Cost‑of‑illness studies in nine Central and Eastern European countries

A nyílt hozzáférést az EISZ és a kiadó között létrejött "Read and Publish" szerződés biztosította. Open access was provided "Read and Publish" contract between EIS and the publisher.

Abstract

Background To date, a multi-country review evaluating the cost-of-illness (COI) studies from the Central and Eastern European (CEE) region has not yet been published. Our main objective was to provide a general description about published COI studies from CEE. Methods A systematic search was performed between 1 January 2006 and 1 June 2017 in Medline, EMBASE, The Cochrane Library, CINAHL, and Web of Science to identify all relevant COI studies from nine CEE countries. COI studies reporting costs without any restrictions by age, co-morbidities, or treatment were included. Methodology, publication standards, and cost results were analysed. Results We identifed 58 studies providing 83 country-specifc COI results: Austria (n=9), Bulgaria (n=16), Croatia (n=3), the Czech Republic (n=10), Hungary (n=24), Poland (n=11), Romania (n=3), Slovakia (n=3), and Slovenia (n=4). Endocrine, nutritional, and metabolic diseases (18%), neoplasms (12%), infections (11%), and neurological disorders (11%) were the most frequently studied clinical areas, and multiple sclerosis was the most commonly studied disease. Overall, 57 (98%) of the studies explicitly stated the source of resource use data, 45 (78%) the study perspective, 34 (64%) the costing method, and 24 (58%) reported at least one unit costs. Regardless of methodological diferences, a positive relationship was observed between costs of diseases and countries’ per capita GDP. Conclusions Cost-of-illness studies varied considerably in terms of methodology, publication practice, and clinical areas. Due to these heterogeneities, transferability of the COI results is limited across Central and Eastern European countries.